ACIP Meeting for Hepislav-B

In February of 2018 the Advisory Committee on Immunization Practices (ACIP) met to approve the Hepislav-B vaccine. This vaccine produced 14 Myocardial Infarctions (Heart attacks) in the group receiving Hepislav B vaccination versus two in the control group (other Hep B vaccine). Despite legitimate questions from doctors, the vaccine was unanimously approved for use.

You can watch the full meeting here: